Does Skyrizi (risankizumab) need a loading dose for plaque psoriasis?
For plaque psoriasis, Skyrizi dosing does not use a traditional “loading dose” pattern. Instead, the standard schedule is built around an early set of doses (commonly described as “starter” dosing) before moving to maintenance intervals.
For adults with moderate-to-severe plaque psoriasis, the typical regimen is:
- 150 mg (given as two 75 mg injections) at weeks 0 and 4
- Then 150 mg every 12 weeks starting at week 16
That weeks 0 and 4 dosing is often what people mean when they search for a “loading dose.” The maintenance dosing then becomes every 12 weeks thereafter.
What is the exact timing schedule (week-by-week) in psoriasis?
If you’re looking for the practical “when do I take it” timeline:
- Week 0: dose
- Week 4: dose
- Week 16: first dose in the every-12-week maintenance period
- Then every 12 weeks after that (week 28, 40, 52, etc.)
Are there different dosing rules if you’re switching from another psoriasis medicine?
The information provided here is about the standard Skyrizi plaque psoriasis regimen. When people switch therapies (for example, from biologics, methotrexate, or phototherapy), clinicians typically decide:
- when to start Skyrizi relative to the last dose of the prior treatment
- whether to continue or taper other systemic therapies
Those decisions depend on the prior drug, your infection history, and how long you’ve been controlled. The injection schedule above is still the Skyrizi psoriasis schedule once treatment begins.
Do loading-dose concepts apply differently for other indications?
Skyrizi also treats other conditions (notably psoriatic arthritis and Crohn’s disease). Dosing schedules can differ by indication. If your question is specifically about plaque psoriasis, the weeks 0 and 4 followed by every-12-weeks approach is the relevant regimen.
If you tell me which form you’re using (auto-injector vs prefilled syringe) and the exact indication (plaque psoriasis vs another condition), I can map the schedule to the exact dosing instructions you’ll see on the prescribing information.
Sources
No DrugPatentWatch.com sources were used because the request was about dosing (not patents or exclusivity).